{
  "name" : "direct.sci-hub.se_www.ncbi.nlm.nih.gov_c6daf49b5fb45bdb42762d4d49782698_www.ncbi.nlm.nih.gov@pmc5052420.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial",
    "authors" : [ "Hamid Reza Rahimi", "Amir Hooshang Mohammadpour", "Mostafa Dastani", "Reza Jaafari", "Khalil Abnous", "Majid Ghayour Mobarhan", "Reza Kazemi Oskuee" ],
    "emails" : [ "oskueekr@mums.ac.ir" ],
    "sections" : [ {
      "heading" : null,
      "text" : "AJP, Vol. 6, No. 5, Sep-Oct 2016 567\nMedical Sciences, Mashhad, Iran Article history: Received: May 28, 2015 Received in revised form: Aug 09, 2015 Accepted: Aug 22, 2015 Vol. 6, No. 5, Sep-Oct 2016, 567-577. * Corresponding Author: Tel: +985138002301 Fax: +985138002287 oskueekr@mums.ac.ir Keywords: Curcumin HbA1c Fast blood glucose Lipid profile\nPlease cite this paper as Rahimi HR, Mohammadpour AH, Dastani M, Jafari MR, Abnous K, Mobarhan MG, Kazemi Oskuee R.The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial.Avicenna J Phytomed, 2016; 6 (5): 567-577.\nAJP, Vol. 6, No. 5, Sep-Oct 2016 568"
    }, {
      "heading" : "Introduction",
      "text" : "Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both or insulin resistance in skeletal muscle, liver and adipose tissues with a failure of b-cell compensation and a relative insulin deficiency (Association 2013; Pettitt et al. 2014).\nThe prevalence of diabetes globally was estimated to be 2.8% in 2000 and 4.4% in 2030 and is higher in men than women (Wild et al. 2004). There are 23.6 million children and adults in the United States, or 7.8% of the population in the USA who have diabetes. While an estimated number of 17.9 million have been diagnosed with diabetes, unfortunately, 5.7 million people (nearly one-quarter) are unaware that they have the disease. The Iranian diabetic population is estimated to be more than 1.5 million (Larejani and Zahedi 2001).\nFree fatty acid metabolites could activate the serine kinase pathway. This signaling pathway influences insulin signaling and insulin receptor functions (Figure 1)(Saini 2010).\nCurcumin is a very active component which comes from the root of turmeric (in Farsi it is called Zardchobeh) (Chuengsamarn et al. 2014; Rahimi and Kazemi Oskuee 2014).\nThe chemical name of curcumin is diferuloylmethane or (1E, 6E)-1, 7-bis (4- hydroxy-3-methoxyphenyl)- 1, 6- heptadiene-3, 5-dione (Hatcher et al. 2008; Santel et al. 2008). Curcumin has antioxidative, anti-inflammatory, chemopreventive, and chemotherapeutic activity(Menon and Sudheer 2007; Sandur et al. 2007) with no significant side effects (Rahimi and Kazemi Oskuee 2014) it can also regulate multiple cell signaling pathways(Gupta et al. 2013).\nNuclear factor-κB (NF-κB) signaling pathway is one of the most important pathways in the cellular and molecular mechanisms of inflammation. In this cellular signaling pathway, cytokines and\nadhesion molecules are secreted. According to the molecular studies, curcumin inhibits NF-κB signaling pathway, which could regulate cytokines production and influence the immune response. Curcumin suppresses some genes expression, especially cytokines genes. Curcumin could down-regulate the expression of TNF α, IL-1, IL-6, IL-8, adhesion molecules (ICAM, VCAM), Creactive protein (Rahimi and Kazemi Oskuee 2014; Rahimi et al. 2015).\nCurcumin can have a therapeutic effect onall human chronic diseases such as asthma, bronchitis, inflammatory bowel disease, rheumatoid arthritis, coronary artery disease, atherosclerosis plaque stabilizing, diabetes mellitus, obesity, fatty liver, metabolic syndrome, depression, cancer, and allergy (Aggarwal and Harikumar 2009).\nCurcumin administration in the prediabetic population decreased the number of pre-diabetic individuals who eventually developed type-2 diabetes mellitus properly (T2DM) (Chuengsamarn et al. 2012).\nAJP, Vol. 6, No. 5, Sep-Oct 2016 569"
    }, {
      "heading" : "Nano-curcumin",
      "text" : "Nano-Curcumin is a registered curcumin product (SinaCurcumin®) for oral use which has been developed in Nanotechnology Research Center of Mashhad University of Medical Sciences, Mashhad, Iran and marketed by Exir Nano Sina Company in Tehran-Iran (IRC:1228225765). Each soft gel of Nanocurcumin contains 80 mg of curcumin in the form of nano-micelle. The oral absorption of curcumin is very poor due to its hydrophobic nature. However, Nanocurcumin has a significantly higher bioavailability after oral use compared to the simple powder of curcumin (Rahimi, Jaafari et al. 2015).\nIn the present study, we examined the effect of Nano micelle curcumin on HbA1C, fasting blood glucose and lipid profile in diabetic subjectsin comparison with the placebo group."
    }, {
      "heading" : "Materials and Methods",
      "text" : ""
    }, {
      "heading" : "Study design and participants",
      "text" : "A double blind randomized placebocontrol add-on clinical trial (registration code: IRCT2013081114330N1) was set up in Mashhad University of medical Sciences.\nSeventy type-2 diabetic patients (fasting blood glucose (FBG) ≥ 126 mg/dl or 2-hr postprandial blood glucose ≥200 mg/dl) were randomly assigned to Nano-curcumin (as nano-micelle 80 mg/day) or placebo for 3 months in a double blind randomized clinical trial. According to the ethical issues all other necessary medications were given to subjects, so, this study is an add-on therapy. All patients were observed by the same researcher during this study."
    }, {
      "heading" : "Randomization procedures",
      "text" : "After screening process, diet and lifestyle training were done face-to-face. All subjects were randomly assigned to either the Nano-curcumin (as nano-micelle 80 mg/day) or placebo-treated group (control condition) using a fixed\nrandomization scheme based on random numbers provided by a computer software. The subjects were informed that two methods of interventions were being evaluated (Figure 2)."
    }, {
      "heading" : "Inclusion criteria",
      "text" : "Subjectswho were included in the\npresent study were:\nSuspected CAD by the selected cardiologist, Male/ Female older than 18 years of age, and they understood the study procedures and agreed to participate.\nExclusion criteria for case and control group\nPregnant and breast-feeding patients were excluded from the present study. In addition, based on the case and control subject’s past medical history taken by the cardiologist, those who reported any of the following diseases were also excluded from the study:Rheumatic disease, chronic liver disease, renal disease, any type of cancer, infectious disease in the last 3 months, people with any surgical procedures in the preceding 3 months, subjects who had a history of angioplasty or coronary by-pass graft surgery, subjects who had a traumatic or major immunologic disease, subjects who were usingsteroids, penicillin, oral contraceptive or hormone replacement therapy. Also,subjects with any inflammatory\nAJP, Vol. 6, No. 5, Sep-Oct 2016 570\ndisease such as inflammatory bowel disease, psoriasis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, autoimmune thyroiditis were excluded from the study (de Freitas, Pinheiro, Miranda, Thiers, de Barros Vieira, Pernambuco and Pe 2001; KazemiBajestani, Ghayour-Mobarhan, Ebrahimi, Moohebati, Esmaeili and Ferns 2008; MJ Zibaee Nezhad, P Ghanbari, B Shahryari and Aghasadeghi 2009)."
    }, {
      "heading" : "Collecting subjects' data",
      "text" : "A general questionnaire was used to obtain information including demographic data and anthropometric parameters. According to the standard procedures, blood pressure was measured using a mercury sphygmomanometer and periodical validity and reliability of the instrument was checked. Height was measured using a wall-mounted stadiometer. Weight was measured using electronic scales while the subject was wearing light clothing without shoes."
    }, {
      "heading" : "Laboratory tests",
      "text" : "Blood samples were obtained in the early morning after an overnight fasting. Fasting blood samples (10 ml) were collected into plain Vacutainer™ tubes, for lipid profile, HbA1C.For measurement of fasting blood glucose, blood was taken into Vacutainer™ tubes containing fluoride-oxalate (Kazemi-Bajestani, Ghayour-Mobarhan, Ebrahimi, Moohebati, Esmaeili and Ferns 2007).\nBlood samples were centrifuged for plasma separation (4000 RPM, 4 min). Total cholesterol, low density lipoprotein cholesterol, high density lipoprotein, cholesterol, and glucose were measured using routine techniques by a Cobas autoanalyser system (ABX Diagnostics, Montpellier, France) (Kazemi-Bajestani et al. 2007).\nThe results of the fasting blood sugar (FBS) < 110 mg/dl were interpreted using the American Diabetic Association criteria: normal values between 110 and\n126 mg/dl, and those > 126 mg/dl are considered as impaired fasting glucose (IFG) and DM, respectivelyall(Pekkanen e al. 1999; Kazemi-Bajestani et al. 2007)."
    }, {
      "heading" : "Ethical issues",
      "text" : "All participants were provided with information about the study both verbally and by written informed consent. All those who hadthe exclusion criteria including those who preferred not to attend at any stage were withdrawn from the study. Each patient gave informed written consent to participate in the study, which was approved by the Ethics Committee of Mashhad University of Medical Sciences. This form was agreed and completed by all subjects. The investigation conforms to the principles outlined in the Declaration of Helsinki."
    }, {
      "heading" : "Sample Size",
      "text" : "Sample size was calculated using frequency data of previous studies (Chuengsamarn, Rattanamongkolgul, Phonrat, Tungtrongchitr and Jirawatnotai 2014; Ghorbani, Hekmatdoost and Mirmiran 2014; Nauck, Meininger, Sheng, Terranella and Stein 2007) with an 80% power, 5% level of significance, and a SD of 35.3. We enrolled at least 35 subjects in each treatment group."
    }, {
      "heading" : "Statistical analysis",
      "text" : "All statistical analyses were performed using SPSS for (of) Windows™, version 11.5 software package (SPSS Inc., Chicago, IL, USA). At first, quantitative data were assessed using KolmogorovSmirnov tests to check normality. Data were expressed as Mean ± SD for parameters with a normal distribution or median and interquartile range for nonnormally distributed data. Group comparisons were performed using sample T-Test or Mann-Whitney U test (in case of non-normally distributed data). A twosided p value < 0.05 was considered statistically significant.\nAJP, Vol. 6, No. 5, Sep-Oct 2016 571"
    }, {
      "heading" : "Results",
      "text" : "Baseline demographic and biochemical serum parameters are matched (such as age, sex, body mass index, smoking habit, hypertension, fasting blood glucose, HbA1c, estimated Average Glucose\n(eAG), total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglyceride) theyshowed) no statistically significant difference between the groups(Tables 1 and 2).\nIn Table 2, body mass index, fasting blood glucose, HbA1C, estimated Average Glucose (eAG), total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglyceride were compared between the 2\ngroups after the intervention.Curcumin improved FBG, HbA1c, BMI, and eAG, but had no effect on LDL, HDL, TG and TC(Table 2).\nPairedt test was used to compare FBG,\nHbA1c, eAG, TG, TC, LDL-C, and HDL-\nAJP, Vol. 6, No. 5, Sep-Oct 2016 572\nC for each subject before and after the\nintervention. Regarding all above-\nmentioned variables, in curcumin-treated\ngroup, statistically significant differences\nwere found before and after the\nintervention (p=0.049, p<0.001, p<0.001,\np=0.018, p=0.01, p=0.014, and p<0.001,\nrespectively). However, in placebo group,\nthere were no differences between the\nresults of FBG, HbA1c, eAG, TG, TC,\nLDL-C, and HDL-C in baseline and\nendpoint results (p=0.204, p=0.521,\np=0.521, p=0.254, p=0.316, p=0.323, and\np=0.387)(Table 2 and 3 and Figures 3 and\n4).\nDetermination of longitudinal changes of FBG, HbA1c, eAG, TG, TC, LDL-C, HDL-C, and BMI before and after of this is shown in Table 3. Significant difference was found between groups in HbA1c,\neAG, LDL-C, and BMI (p<0.05) (Table 3).\nΔ=after- before for ech value, BMI: Body Mass Index, FBG: Fasting blood glucose, TC: total cholesterol, HDLC: High density lipoprotein- cholesterol, LDL-C: Low density lipoprotein- cholesterol, TG: triglyceride, IQR: Interquartile Range.eAG: estimated Average Glucose =(28.7×HbA1CHbA1c)-46.7\nAJP, Vol. 6, No. 5, Sep-Oct 2016 573\nAs noted before (Figure 2), 10 patients in both groups did not complete the procedure of this study, due to long distance to the institution, their health insurance and crowdedness of Ghaem Academic hospital, Mashhad, Iran."
    }, {
      "heading" : "Discussion",
      "text" : "A large number of studies has been conducted on the physicochemical traits and pharmacological effects of curcumin on different diseases like cardiovascular diseases, diabetes, cancer, rheumatoid arthritis, Alzheimer’s, inflammatory bowel disease (IBD), or even wound healing, due to its minor toxicity (Soni and Kuttan 1992; Garodia et al. 2007; Liu et al. 2013). The use of curcumin for treatment of these conditions has revealed that curcumin modulates several transcription factors, kinases, growth factors, cytokines, and\nsome other enzymes (Kakarala et al. 2010; Thamake et al. 2011; Venkatesha et al. 2011). Other studies showed that curcumin has anti-diabetic activities (Yeh et al. 2003; Hsu and Cheng 2007).\nInsulin resistance (IR) is the backbone of T2DM (Na et al. 2011); It was reported that curcumin could break IR (Neerati et al. 2014). Also, curcumin could increase the activation of PPAR-γ (Nishiyama et al. 2005). PPAR-γ activity suppresses lowdensity lipoprotein (LDL) receptor and it could be used as a treatment of hypercholesterolemia (Kang and Chen 2009).\nCurcumin may prevent diabetes mellitus microvascular and macrovascular complications (Sharma et al. 2006; Muthenna et al. 2009).\nA great problem that should be considered is that several studies on chemical structure of curcumin (a polyphenolic compound) have shown that\nAJP, Vol. 6, No. 5, Sep-Oct 2016 574\nthis substance has a poor bioavailability (Chainani-Wu 2003; Anand et al. 2007; Hatcher, Planalp et al. 2008). In addition, it has a low absorption, fast metabolism, and fast systemic elimination (Anand, Kunnumakkara et al. 2007).\nTo overcome curcumin's poor bioavailability, nano-micelle containing curcumin which is a registered curcumin product (SinaCurcumin®) was prepared for oral use. These nano-micelles are prepared from GRAS (generally recognized as safe) pharmaceutical excipients and C3-complex form of curcumin. The percentage of encapsulation of curcumin in this nano-micelle is close to 100% and their sizes are around 10 nm. Nano-curcumin has a significantly higher bioavailability after oral use as compared to simple powder of curcumin due to the following reasons:An intact layer of water is on the surface of intestinal epithelial cells (unstirred water layer), so any medication should pass this barrier (Smithson et al. 1981), this is a confronting barrier for lipophilic molecules such as curcumin. Bile salts largely facilitates absorption and soluble substances such as lipophilic vitamins, lipids, fatty acids and cholesterol(Howles 2010) and also the same happens for curcumin as nano-micelles. After oral administration, soft gel of Nano-curcumin opens in the stomach in less than 15 minutes and will be diffused to the small intestine; this product has a higher bioavailability than other similar products(Rahimi and Kazemi Oskuee 2014).\nIn this clinical trial, we found that Nano-curcumin reduces FBG and HbA1c during 3 months of therapy; it could also significantly reduce eAG and lipid profile parameters. Obesity is one of the most important factors in IR and T2DM development (Weisberg et al. 2008). In this research, we found that curcumin has a good influence on BMI in diabetic patients.\nAlso, it was found that one-month oral administration of curcumin (1 gram/day) could reduce triglycerides concentrations in obese subjects (Mohammadi et al. 2013).\nAccording to the Framingham Heart Study, level of HbA1c has a great association with cardiovascular disease and T2DM (Singer et al. 1992).\nMoreover, it was shown that low dose of oral curcumin could reduce LDL-C and TC (Alwi et al. 2008). We compared serum levels of TC, TG, LDL-C, and HDL-C, before and after the treatment and significant differences were found for each subject in Nano-curcumin group."
    }, {
      "heading" : "Acknowledgement",
      "text" : "Mashhad University of Medical Science Research Council supported this research. Data presented here was from a PhD thesis. In addition, authors would like to thank Dar Al-Shifa Imam Reza Medical laboratory staffs, Mrs. Sareh Ejlali for her kind cooperation, and Dr Taghiabadi drugstore."
    }, {
      "heading" : "Conflict of interest",
      "text" : "The authors have no conflict of interests\nto declare."
    } ],
    "references" : [ {
      "title" : "Potential therapeutic effects of curcumin, the antiinflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune",
      "author" : [ "Aggarwal BB", "Harikumar KB" ],
      "venue" : null,
      "citeRegEx" : "BB and KB.,? \\Q2009\\E",
      "shortCiteRegEx" : "BB and KB.",
      "year" : 2009
    }, {
      "title" : "S.2008.The effect of curcumin on lipid level in patients with acute coronary syndrome",
      "author" : [ "I Alwi", "T Santoso", "S Suyono", "B Sutrisna", "FD Suyatna", "SB Kresno", "Ernie" ],
      "venue" : "Acta Med Indones,",
      "citeRegEx" : "Alwi et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Alwi et al\\.",
      "year" : 2008
    }, {
      "title" : "Bioavailability of curcumin: problems and promises",
      "author" : [ "P Anand", "AB Kunnumakkara", "RA Newman", "BB. Aggarwal" ],
      "venue" : "Mol Pharm, 46: 807-818.",
      "citeRegEx" : "Anand et al\\.,? 2007",
      "shortCiteRegEx" : "Anand et al\\.",
      "year" : 2007
    }, {
      "title" : "2013.Diagnosis and classification of diabetes mellitus",
      "author" : [ "Association AD" ],
      "venue" : "Diabetes care,36:",
      "citeRegEx" : "AD.,? \\Q2013\\E",
      "shortCiteRegEx" : "AD.",
      "year" : 2013
    }, {
      "title" : "2012.Curcumin extract for prevention of type 2 diabetes",
      "author" : [ "S Chuengsamarn", "S Rattanamongkolgul", "R Luechapudiporn", "C Phisalaphong", "S. Jirawatnotai" ],
      "venue" : "Diabetes Care,",
      "citeRegEx" : "Chuengsamarn et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Chuengsamarn et al\\.",
      "year" : 2012
    }, {
      "title" : "2014.Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized",
      "author" : [ "S Chuengsamarn", "S Rattanamongkolgul", "B Phonrat", "R Tungtrongchitr", "S. Jirawatnotai" ],
      "venue" : null,
      "citeRegEx" : "Chuengsamarn et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Chuengsamarn et al\\.",
      "year" : 2014
    }, {
      "title" : "Assessment of antiinflammatory effect of 830nm laser light using C-reactive protein levels",
      "author" : [ "AC Freitas", "AL Pinheiro", "P Miranda", "FA Thiers", "AL. Vieira" ],
      "venue" : "Braz Dent J, 12: 187-190.",
      "citeRegEx" : "Freitas et al\\.,? 2001",
      "shortCiteRegEx" : "Freitas et al\\.",
      "year" : 2001
    }, {
      "title" : "2011.Alcoholic liver disease: pathogenesis and new therapeutic",
      "author" : [ "B Gao", "R. Bataller" ],
      "venue" : "targets. Gastroenterology,",
      "citeRegEx" : "Gao and Bataller,? \\Q2011\\E",
      "shortCiteRegEx" : "Gao and Bataller",
      "year" : 2011
    }, {
      "title" : "BB.2007.From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer",
      "author" : [ "P Garodia", "H Ichikawa", "N Malani", "G Sethi", "Aggarwal" ],
      "venue" : "J Soc Integr Oncol,",
      "citeRegEx" : "Garodia et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Garodia et al\\.",
      "year" : 2007
    }, {
      "title" : "2014.Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin",
      "author" : [ "Z Ghorbani", "A Hekmatdoost", "P. Mirmiran" ],
      "venue" : "Int J Endocrinol Metab,",
      "citeRegEx" : "Ghorbani et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Ghorbani et al\\.",
      "year" : 2014
    }, {
      "title" : "Therapeutic roles of curcumin: lessons learned from clinical",
      "author" : [ "SC Gupta", "S Patchva", "BB.2013. Aggarwal" ],
      "venue" : "trials.AAPS J,",
      "citeRegEx" : "Gupta et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Gupta et al\\.",
      "year" : 2013
    }, {
      "title" : "Curcumin: from ancient medicine to current clinical trials",
      "author" : [ "H Hatcher", "R Planalp", "J Cho", "FM Torti", "SV. Torti" ],
      "venue" : "Cell Mol Life Sci, 65: 1631-1652.",
      "citeRegEx" : "Hatcher et al\\.,? 2008",
      "shortCiteRegEx" : "Hatcher et al\\.",
      "year" : 2008
    }, {
      "title" : "2007.Clinical studies with curcumin",
      "author" : [ "Hsu CH", "Cheng AL" ],
      "venue" : "Adv Exp Med Biol,",
      "citeRegEx" : "CH and AL.,? \\Q2007\\E",
      "shortCiteRegEx" : "CH and AL.",
      "year" : 2007
    }, {
      "title" : "2010.Targeting breast stem cells with the cancer",
      "author" : [ "M Kakarala", "DE Brenner", "H Korkaya", "C Cheng", "K Tazi", "C Ginestier", "S Liu", "G Dontu", "MS. Wicha" ],
      "venue" : null,
      "citeRegEx" : "Kakarala et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Kakarala et al\\.",
      "year" : 2010
    }, {
      "title" : "2009.Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells",
      "author" : [ "Q Kang", "A. Chen" ],
      "venue" : "Br J Pharmacol,",
      "citeRegEx" : "Kang and Chen,? \\Q2009\\E",
      "shortCiteRegEx" : "Kang and Chen",
      "year" : 2009
    }, {
      "title" : "GA.2007.C-reactive protein associated with coronary artery disease in Iranian patients with angiographically",
      "author" : [ "SM Kazemi-Bajestani", "M Ghayour-Mobarhan", "M Ebrahimi", "M Moohebati", "HA Esmaeili", "Ferns" ],
      "venue" : null,
      "citeRegEx" : "Kazemi.Bajestani et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Kazemi.Bajestani et al\\.",
      "year" : 2007
    }, {
      "title" : "2001.Epidemiology of diabetes mellitus in Iran",
      "author" : [ "B Larejani", "F. Zahedi" ],
      "venue" : "Ir J Diabetes Met,",
      "citeRegEx" : "Larejani and Zahedi,? \\Q2001\\E",
      "shortCiteRegEx" : "Larejani and Zahedi",
      "year" : 2001
    }, {
      "title" : "2013.Recent progress in studying curcumin and its nano-preparations for cancer therapy",
      "author" : [ "J Liu", "S Chen", "L Lv", "L Song", "S Guo", "S. Huang" ],
      "venue" : "Curr pharm des,",
      "citeRegEx" : "Liu et al\\.,? \\Q1993\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 1993
    }, {
      "title" : "Antioxidant and anti-inflammatory properties of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease",
      "author" : [ "Menon VP", "Sudheer AR" ],
      "venue" : null,
      "citeRegEx" : "VP and AR.2007.,? \\Q2007\\E",
      "shortCiteRegEx" : "VP and AR.2007.",
      "year" : 2007
    }, {
      "title" : "C-Reactive Protein in Angiographically Documented Stable Coronary Disease",
      "author" : [ "MZ Nezhad", "P Ghanbari", "B Shahryari", "K.2009. Aghasadeghi" ],
      "venue" : "Ir Cardiovas Res J,",
      "citeRegEx" : "Nezhad et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Nezhad et al\\.",
      "year" : 2009
    }, {
      "title" : "2013.Effects of supplementation with curcuminoids on dyslipidemia in obese",
      "author" : [ "A Mohammadi", "A Sahebkar", "M Iranshahi", "M Amini", "R Khojasteh", "M GhayourMobarhan", "GA. Ferns" ],
      "venue" : null,
      "citeRegEx" : "Mohammadi et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Mohammadi et al\\.",
      "year" : 2013
    }, {
      "title" : "2009.\"Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance",
      "author" : [ "P Muthenna", "P Suryanarayana", "SK Gunda", "JM Petrash", "GB. Reddy" ],
      "venue" : null,
      "citeRegEx" : "Muthenna et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Muthenna et al\\.",
      "year" : 2009
    }, {
      "title" : "2011.Curcumin improves insulin resistance in skeletal muscle of rats",
      "author" : [ "LX Na", "YL Zhang", "Y Li", "LY Liu", "R Li", "T Kong", "CH. Sun" ],
      "venue" : "Nutr Metab Cardiovasc Dis,",
      "citeRegEx" : "Na et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Na et al\\.",
      "year" : 2011
    }, {
      "title" : "Sitagliptin Study 024 Group. 2007.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin",
      "author" : [ "MA Nauck", "G Meininger", "D Sheng", "L Terranella", "PP Stein" ],
      "venue" : null,
      "citeRegEx" : "Nauck et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Nauck et al\\.",
      "year" : 2007
    }, {
      "title" : "AK.2014.Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus",
      "author" : [ "P Neerati", "R Devde", "Gangi" ],
      "venue" : "Phytother Res,",
      "citeRegEx" : "Neerati et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Neerati et al\\.",
      "year" : 2014
    }, {
      "title" : "Curcuminoids and sesquiterpenoids in turmeric (Curcuma",
      "author" : [ "T Nishiyama", "T Mae", "H Kishida", "M Tsukagawa", "Y Mimaki", "M Kuroda", "Y Sashida", "K Takahashi", "T Kawada", "K Nakagawa", "M. Kitahara" ],
      "venue" : null,
      "citeRegEx" : "Nishiyama et al\\.,? \\Q2005\\E",
      "shortCiteRegEx" : "Nishiyama et al\\.",
      "year" : 2005
    }, {
      "title" : "1999.Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study",
      "author" : [ "J Pekkanen", "J Tuomilehto", "Q Qiao", "P Jousilahti", "J Lindström", "DS. Group" ],
      "venue" : null,
      "citeRegEx" : "Pekkanen et al\\.,? \\Q1999\\E",
      "shortCiteRegEx" : "Pekkanen et al\\.",
      "year" : 1999
    }, {
      "title" : "Curcumin: Reintroduced Therapeutic Agent from Traditional",
      "author" : [ "HR Rahimi", "MR Jaafari", "AH Mohammadpour", "K Abnous", "M Ghayour Mobarhan", "E Ramezanzadeh", "F Mousavi", "R. Kazemi Oskuee" ],
      "venue" : null,
      "citeRegEx" : "Rahimi et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Rahimi et al\\.",
      "year" : 2015
    }, {
      "title" : "Curcumin From Traditional Iranian Medicine to Molecular Medicine",
      "author" : [ "HR Rahimi", "R. Kazemi Oskuee" ],
      "venue" : "Razavi Int J Med, 2: 3-4.",
      "citeRegEx" : "Rahimi and Oskuee,? 2014",
      "shortCiteRegEx" : "Rahimi and Oskuee",
      "year" : 2014
    }, {
      "title" : "2010.Molecular mechanisms of insulin resistance in type 2 diabetes mellitus",
      "author" : [ "V. Saini" ],
      "venue" : "World J Diabetes,",
      "citeRegEx" : "Saini,? \\Q2010\\E",
      "shortCiteRegEx" : "Saini",
      "year" : 2010
    }, {
      "title" : "Birkenmeier G.2008.Curcumin inhibits glyoxalase 1—a possible link to its antiinflammatory and anti-tumor activity",
      "author" : [ "R Gebhardt", "M Platzer", "T Weiss", "MA Vijayalakshmi", "M Krüger" ],
      "venue" : null,
      "citeRegEx" : "W et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "W et al\\.",
      "year" : 2008
    }, {
      "title" : "Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats",
      "author" : [ "S Sharma", "SK Kulkarni", "K. Chopra" ],
      "venue" : "Clin Exp Pharmacol Physiol, 33: 940-945.",
      "citeRegEx" : "Sharma et al\\.,? 2006",
      "shortCiteRegEx" : "Sharma et al\\.",
      "year" : 2006
    }, {
      "title" : "Intestinal diffusion barrier: unstirred water layer or membrane surface mucous coat",
      "author" : [ "KW Smithson", "DB Millar", "LR Jacobs", "GM. Gray" ],
      "venue" : "Science, 214: 1241-1244.",
      "citeRegEx" : "Smithson et al\\.,? 1981",
      "shortCiteRegEx" : "Smithson et al\\.",
      "year" : 1981
    }, {
      "title" : "1992.Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers",
      "author" : [ "K Soni", "R. Kuttan" ],
      "venue" : "Indian J Physio Pharmacol,",
      "citeRegEx" : "Soni and Kuttan,? \\Q1992\\E",
      "shortCiteRegEx" : "Soni and Kuttan",
      "year" : 1992
    }, {
      "title" : "Vishwanatha JK.2011.Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homobifunctional spacer for active targeting",
      "author" : [ "SI Thamake", "SL Raut", "AP Ranjan", "Z Gryczynski" ],
      "venue" : null,
      "citeRegEx" : "Thamake et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Thamake et al\\.",
      "year" : 2011
    }, {
      "title" : "2011.Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis",
      "author" : [ "SH Venkatesha", "BM Berman", "KD. Moudgil" ],
      "venue" : "Bioorg med chem,",
      "citeRegEx" : "Venkatesha et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Venkatesha et al\\.",
      "year" : 2011
    }, {
      "title" : "Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity",
      "author" : [ "SP Weisberg", "R Leibel", "DV.2008. Tortoriello" ],
      "venue" : null,
      "citeRegEx" : "Weisberg et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Weisberg et al\\.",
      "year" : 2008
    }, {
      "title" : "2004.Global prevalence of diabetes",
      "author" : [ "S Wild", "G Roglic", "A Green", "R Sicree", "H. King" ],
      "venue" : null,
      "citeRegEx" : "Wild et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Wild et al\\.",
      "year" : 2004
    }, {
      "title" : "Systematic review of herbs and dietary supplements for glycemic control in diabetes",
      "author" : [ "GY Yeh", "DM Eisenberg", "TJ Kaptchuk", "RS. Phillips" ],
      "venue" : "Diabetes Care, 26: 1277-1294.",
      "citeRegEx" : "Yeh et al\\.,? 2003",
      "shortCiteRegEx" : "Yeh et al\\.",
      "year" : 2003
    } ],
    "referenceMentions" : [ {
      "referenceID" : 37,
      "context" : "2030 and is higher in men than women (Wild et al. 2004).",
      "startOffset" : 37,
      "endOffset" : 55
    }, {
      "referenceID" : 29,
      "context" : "This signaling pathway influences insulin signaling and insulin receptor functions (Figure 1)(Saini 2010).",
      "startOffset" : 93,
      "endOffset" : 105
    }, {
      "referenceID" : 5,
      "context" : "Curcumin is a very active component which comes from the root of turmeric (in Farsi it is called Zardchobeh) (Chuengsamarn et al. 2014; Rahimi and Kazemi Oskuee 2014).",
      "startOffset" : 109,
      "endOffset" : 166
    }, {
      "referenceID" : 10,
      "context" : "2007) with no significant side effects (Rahimi and Kazemi Oskuee 2014) it can also regulate multiple cell signaling pathways(Gupta et al. 2013).",
      "startOffset" : 124,
      "endOffset" : 143
    }, {
      "referenceID" : 27,
      "context" : "Curcumin could down-regulate the expression of TNF α, IL-1, IL-6, IL-8, adhesion molecules (ICAM, VCAM), Creactive protein (Rahimi and Kazemi Oskuee 2014; Rahimi et al. 2015).",
      "startOffset" : 123,
      "endOffset" : 174
    }, {
      "referenceID" : 4,
      "context" : "Curcumin administration in the prediabetic population decreased the number of pre-diabetic individuals who eventually developed type-2 diabetes mellitus properly (T2DM) (Chuengsamarn et al. 2012).",
      "startOffset" : 169,
      "endOffset" : 195
    }, {
      "referenceID" : 15,
      "context" : "Total cholesterol, low density lipoprotein cholesterol, high density lipoprotein, cholesterol, and glucose were measured using routine techniques by a Cobas autoanalyser system (ABX Diagnostics, Montpellier, France) (Kazemi-Bajestani et al. 2007).",
      "startOffset" : 216,
      "endOffset" : 246
    }, {
      "referenceID" : 15,
      "context" : "The results of the fasting blood sugar (FBS) < 110 mg/dl were interpreted using the American Diabetic Association criteria: normal values between 110 and 126 mg/dl, and those > 126 mg/dl are considered as impaired fasting glucose (IFG) and DM, respectivelyall(Pekkanen e al. 1999; Kazemi-Bajestani et al. 2007).",
      "startOffset" : 259,
      "endOffset" : 310
    }, {
      "referenceID" : 33,
      "context" : "A large number of studies has been conducted on the physicochemical traits and pharmacological effects of curcumin on different diseases like cardiovascular diseases, diabetes, cancer, rheumatoid arthritis, Alzheimer’s, inflammatory bowel disease (IBD), or even wound healing, due to its minor toxicity (Soni and Kuttan 1992; Garodia et al. 2007; Liu et al. 2013).",
      "startOffset" : 303,
      "endOffset" : 363
    }, {
      "referenceID" : 8,
      "context" : "A large number of studies has been conducted on the physicochemical traits and pharmacological effects of curcumin on different diseases like cardiovascular diseases, diabetes, cancer, rheumatoid arthritis, Alzheimer’s, inflammatory bowel disease (IBD), or even wound healing, due to its minor toxicity (Soni and Kuttan 1992; Garodia et al. 2007; Liu et al. 2013).",
      "startOffset" : 303,
      "endOffset" : 363
    }, {
      "referenceID" : 13,
      "context" : "The use of curcumin for treatment of these conditions has revealed that curcumin modulates several transcription factors, kinases, growth factors, cytokines, and some other enzymes (Kakarala et al. 2010; Thamake et al. 2011; Venkatesha et al. 2011).",
      "startOffset" : 181,
      "endOffset" : 248
    }, {
      "referenceID" : 34,
      "context" : "The use of curcumin for treatment of these conditions has revealed that curcumin modulates several transcription factors, kinases, growth factors, cytokines, and some other enzymes (Kakarala et al. 2010; Thamake et al. 2011; Venkatesha et al. 2011).",
      "startOffset" : 181,
      "endOffset" : 248
    }, {
      "referenceID" : 35,
      "context" : "The use of curcumin for treatment of these conditions has revealed that curcumin modulates several transcription factors, kinases, growth factors, cytokines, and some other enzymes (Kakarala et al. 2010; Thamake et al. 2011; Venkatesha et al. 2011).",
      "startOffset" : 181,
      "endOffset" : 248
    }, {
      "referenceID" : 38,
      "context" : "Other studies showed that curcumin has anti-diabetic activities (Yeh et al. 2003; Hsu and Cheng 2007).",
      "startOffset" : 64,
      "endOffset" : 101
    }, {
      "referenceID" : 22,
      "context" : "Insulin resistance (IR) is the backbone of T2DM (Na et al. 2011); It was reported that curcumin could break IR (Neerati et al.",
      "startOffset" : 48,
      "endOffset" : 64
    }, {
      "referenceID" : 24,
      "context" : "2011); It was reported that curcumin could break IR (Neerati et al. 2014).",
      "startOffset" : 52,
      "endOffset" : 73
    }, {
      "referenceID" : 14,
      "context" : "PPAR-γ activity suppresses lowdensity lipoprotein (LDL) receptor and it could be used as a treatment of hypercholesterolemia (Kang and Chen 2009).",
      "startOffset" : 125,
      "endOffset" : 145
    }, {
      "referenceID" : 31,
      "context" : "Curcumin may prevent diabetes mellitus microvascular and macrovascular complications (Sharma et al. 2006; Muthenna et al. 2009).",
      "startOffset" : 85,
      "endOffset" : 127
    }, {
      "referenceID" : 21,
      "context" : "Curcumin may prevent diabetes mellitus microvascular and macrovascular complications (Sharma et al. 2006; Muthenna et al. 2009).",
      "startOffset" : 85,
      "endOffset" : 127
    }, {
      "referenceID" : 2,
      "context" : "5, Sep-Oct 2016 574 this substance has a poor bioavailability (Chainani-Wu 2003; Anand et al. 2007; Hatcher, Planalp et al. 2008).",
      "startOffset" : 62,
      "endOffset" : 129
    }, {
      "referenceID" : 32,
      "context" : "Nano-curcumin has a significantly higher bioavailability after oral use as compared to simple powder of curcumin due to the following reasons:An intact layer of water is on the surface of intestinal epithelial cells (unstirred water layer), so any medication should pass this barrier (Smithson et al. 1981), this is a confronting barrier for lipophilic molecules such as curcumin.",
      "startOffset" : 284,
      "endOffset" : 306
    }, {
      "referenceID" : 36,
      "context" : "Obesity is one of the most important factors in IR and T2DM development (Weisberg et al. 2008).",
      "startOffset" : 72,
      "endOffset" : 94
    }, {
      "referenceID" : 20,
      "context" : "Also, it was found that one-month oral administration of curcumin (1 gram/day) could reduce triglycerides concentrations in obese subjects (Mohammadi et al. 2013).",
      "startOffset" : 139,
      "endOffset" : 162
    }, {
      "referenceID" : 1,
      "context" : "Moreover, it was shown that low dose of oral curcumin could reduce LDL-C and TC (Alwi et al. 2008).",
      "startOffset" : 80,
      "endOffset" : 98
    } ],
    "year" : 2016,
    "abstractText" : "1 Student Research Committee, Department of Modern Sciences & Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2 Pharmacetical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran 3 Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 4 Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran 5 Pharmaceutical Research Center, Department of Medicinal Chemistry, Mashhad University of Medical Sciences, Mashhad, Iran 6 Neurogenic Inflammation Research Center and Department of Medical Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran",
    "creator" : "Microsoft® Word 2010"
  }
}